- Molecular NameMegestrol
- SynonymMegestrol Acetate; Megestrolo [DCIT]; Megestrolum [INN-Latin]; Megestryl acetate; MGA
- Weight342.479
- Drugbank_IDDB00351
- ACS_NO3562-63-8
- Show 3D model
- LogP (experiment)3.123
- LogP (predicted, AB/LogP v2.0)3.26
- pkaN/A
- LogD (pH=7, predicted)3.26
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.16
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds1
- TPSA54.37
- StatusFDA approved
- AdministrationN/A
- PharmacologyA progesterone derivative with antineoplastic properties used in the treatment of advanced carcinoma of the breast and endometrium. When given in relatively high doses, Megestrol can substantially increase appetite in most individuals, even those with advanced cancer.
- Absorption_valueN/A
- Absorption (description)Variable, but well absorbed orally.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPrimarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.
- Half life34 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityNo serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day.
- LD50 (rat)N/A
- LD50 (mouse)N/A